Sodium-chloride symporter Inhibitors
1 drugsAbout Sodium-chloride symporter
The Sodium-chloride symporter (NCC or TSC) is a membrane protein in the kidneys responsible for reabsorbing sodium and chloride in the distal convoluted tubule. This process is critical for maintaining blood pressure and fluid balance.
The symporter is a therapeutic target in the cardiovascular area, though no genetic evidence currently links it to specific diseases. Targeting this symporter can modulate electrolyte reabsorption to manage hypertension.
One FDA-approved drug, EXFORGE HCT (Novartis), targets the Sodium-chloride symporter for cardiovascular indications. The drug is a small molecule approved in 2009.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Obesity with only 1 trials.
- phase3 represents biological uncertainty with 50% completion.
Top Sodium-chloride symporter Drugs
Novartis is the only company with an approved drug targeting this symporter.
High market concentration suggests significant entry barriers or limited commercial opportunity.
Sodium-chloride symporter Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Sodium-chloride symporter, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
Sodium-chloride symporter Clinical Trials 112 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 23 | 20 | 1 | 2 | 95% |
| Phase 2 | 15 | 12 | 1 | 2 | 92% |
| Phase 3 | 29 | 22 | 5 | 2 | 81% |
| Phase 4 | 45 | 27 | 10 | 8 | 73% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Sodium-chloride symporter Drug Approval Timeline (2009 - 2009)
The first and only drug, EXFORGE HCT, was approved in 2009.
The approval timeline suggests a saturated market with limited recent innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 55 clinical trials targeting Sodium-chloride symporter.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities